{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Manry J"],"funding":["Intramural NIH HHS","NCATS NIH HHS","NCRR NIH HHS","NIAID NIH HHS","NHGRI NIH HHS","NCI NIH HHS","NIH HHS"],"pagination":["e2200413119"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9173764"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["119(21)"],"pubmed_abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing IFN-α, IFN-ω, and/or IFN-β are found in ∼20% of deceased patients across age groups, and in ∼1% of individuals aged <70 y and in >4% of those >70 y old in the general population. With a sample of 1,261 unvaccinated deceased patients and 34,159 individuals of the general population sampled before the pandemic, we estimated both IFR and relative risk of death (RRD) across age groups for individuals carrying autoantibodies neutralizing type I IFNs, relative to noncarriers. The RRD associated with any combination of autoantibodies was higher in subjects under 70 y old. For autoantibodies neutralizing IFN-α2 or IF"],"journal":["Proceedings of the National Academy of Sciences of the United States of America"],"pubmed_title":["The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies."],"pmcid":["PMC9173764"],"funding_grant_id":["ZIA AI001265","R01 AI091707","U19 AI111825","ZIA AI001270","R01 AI088364","R01 AI163029","UL1 TR001866","75N91019D00024","UL1 RR024143","S10 OD018521","U24 HG008956","UM1 HG006504"],"pubmed_authors":["Duvlis S","Megarbane B","Kurolap A","Imagine COVID-Group","Klocperk A","Gervais A","Koning R","Fekkar A","Rodriguez-Gallego C","El Bakkouri J","Bastard P","Lorenzo L","Wauters J","Cognasse F","Bilguvar K","Troya J","van de Beek D","Tharaux PL","Spaan AN","Pan-Hammarstrom Q","Lyonnet S","Rosain J","Ozcelik T","Boisson B","Aiuti A","Riviere JG","Meyts I","Heath JR","Reyes LF","Le Voyer T","Colobran R","COVID Clinicians","Vidaur L","Halwani R","3C-Dijon Study","Mogensen TH","Vasse M","Garcia-Prat M","Michailidis E","Lifton RP","Beziat V","Rice CM","Lagier JC","Pujol A","Triantafyllia V","Monneret G","Boudhabhay I","Paul S","Lau YL","de Lamballerie X","Sharif-Askari FS","Bousfiha AA","Trouillet-Assant S","Mond J","Boyarchuk O","Prando C","Rigo-Bonnin R","Susen S","Dorgham K","NIAID Immune Response to COVID Group","Dupont A","Bourke NM","Castagnoli R","Rowen L","Solanich X","Notarangelo LD","Abel L","Tiberghien P","Philippot Q","Baris-Feldman H","Bondarenko A","Hoffmann HH","Stepanovskyy Y","Dalmau D","Tancevski I","Gorochov G","COVID-STORM Clinicians","Danish CHGE","Raoult D","Biondi A","Leung D","Moncada-Velez M","Cobat A","Bonfanti P","Nukui Y","Holland SM","Delmonte OM","French COVID Cohort Study Group","Dominguez-Garrido E","Kennelly SP","Sene D","Saker K","Tangye SG","CoV-Contact Cohort","Zhang Y","Chauvineau-Grenier A","Venet F","Arias AA","Tsumura M","Anglicheau D","Lampasona V","Burdet C","Danish Blood Donor Study","Zins M","Zhang Q","Duffy D","Piemonti L","COVID Human Genetic Effort","Richard P","Ciceri F","CP-COVID-19 Group","Morel P","Gilardin L","Haljasmagi L","Casari G","de Prost N","Sedkaoui SM","Biggs CM","HGID Lab","Shcherbina A","Casanova JL","Condino-Neto A","Mane S","Peterson P","Gentile S","Tandjaoui-Lambiotte Y","Barreiros LA","Erikstrup C","Sole-Violan J","AlKhater S","Hammarstrom L","Parra-Martinez A","Kann NY","Zhang SY","Anaya JM","Fellay J","Hagin D","Jouanguy E","Shaw E","Tanaka J","Hermine O","Martinez-Picado J","Snow AL","Etablissement Français du Sang Study group","Coulongeat M","Arrestier R","Amsterdam UMC Covid-19 Biobank Investigators","Franco JL","Vinh DC","Belot A","NH-COVAIR Study Group","Sahanic S","Keles S","Dyer AH","Ramirez-Santana C","Haerynck F","Kisand K","Sarekannu K","Maslovskaja J","Nussenzweig MC","Milieu Intérieur Consortium","Puel A","Boucherit S","Gaudet A","Su HC","Luyt CE","Morandeira F","Roussel L","Rosen LB","Garcon P","Marlet J","Cerba Health-Care","Sallette J","Stepanian A","Soler-Palacin P","Vidigal M","Debette S","Eto S","Bouadma L","Amador-Borrero B","Yang R","Metz CN","CONSTANCES cohort","Burrel S","Bizien L","Andreakos E","St. James's Hospital, SARS CoV2 Interest Group","Zatz M","Anderson MS","Manry J","Gregersen PK","Migaud M","Morio T","Planas AM","Poissy J","Imberti L","Okada S","Quintana-Murci L"],"additional_accession":[]},"is_claimable":false,"name":"The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.","description":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing IFN-α, IFN-ω, and/or IFN-β are found in ∼20% of deceased patients across age groups, and in ∼1% of individuals aged <70 y and in >4% of those >70 y old in the general population. With a sample of 1,261 unvaccinated deceased patients and 34,159 individuals of the general population sampled before the pandemic, we estimated both IFR and relative risk of death (RRD) across age groups for individuals carrying autoantibodies neutralizing type I IFNs, relative to noncarriers. The RRD associated with any combination of autoantibodies was higher in subjects under 70 y old. For autoantibodies neutralizing IFN-α2 or IF","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2025-04-04T07:43:41.373Z","creation":"2025-04-04T07:43:41.373Z"},"accession":"S-EPMC9173764","cross_references":{"pubmed":["35576468"],"doi":["10.1073/pnas.2200413119"]}}